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Germany, 4 Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and I.
Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 5 Institut
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Abstract
Background
In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated
malaria, pyronaridine–artesunate demonstrated high efficacy and a safety profile consistent
with that of comparators, except that asymptomatic, mainly mild-to-moderate transient
increases in liver aminotransferases were reported for some patients. Hepatic safety, tolera-
bility, and effectiveness have not been previously assessed under real-world conditions in
Africa.
Methods and findings
This single-arm, open-label, cohort event monitoring study was conducted at 6 health cen-
ters in Cameroon, Democratic Republic of Congo, Gabon, Ivory Coast, and Republic of
Congo between June 2017 and April 2019. The trial protocol as closely as possible resem-
bled real-world clinical practice for the treatment of malaria at the centers. Eligible patients
were adults or children of either sex, weighing at least 5 kg, with acute uncomplicated
malaria who did not have contraindications for pyronaridine–artesunate treatment as per the
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summary of product characteristics. Patients received fixed-dose pyronaridine–artesunate
once daily for 3 days, dosed by body weight, without regard to food intake. A tablet formula-
tion was used in adults and adolescents and a pediatric granule formulation in children and
infants under 20 kg body weight. The primary outcome was the hepatic event incidence,
defined as the appearance of the clinical signs and symptoms of hepatotoxicity confirmed
by a >2× rise in alanine aminotransferase/aspartate aminotransferase (ALT/AST) versus
baseline in patients with baseline ALT/AST >2× the upper limit of normal (ULN). As a sec-
ondary outcome, this was assessed in patients with ALT/AST >2× ULN prior to treatment
versus a matched cohort of patients with normal baseline ALT/AST. The safety population
comprised 7,154 patients, of mean age 13.9 years (standard deviation (SD) 14.6), around
half of whom were male (3,569 [49.9%]). Patients experienced 8,560 malaria episodes; 158
occurred in patients with baseline ALT/AST elevations >2×ULN. No protocol-defined hepatic
events occurred following pyronaridine–artesunate treatment of malaria patients with or
without baseline hepatic dysfunction. Thus, no cohort comparison could be undertaken.
Also, as postbaseline clinical chemistry was only performed where clinically indicated, post-
baseline ALT/AST levels were not systematically assessed for all patients. Adverse events
of any cause occurred in 20.8% (1,490/7,154) of patients, most frequently pyrexia (5.1%
[366/7,154]) and vomiting (4.2% [303/7,154]). Adjusting for Plasmodium falciparum reinfec-
tion, clinical effectiveness at day 28 was 98.6% ([7,369/7,746] 95% confidence interval (CI)
98.3 to 98.9) in the per-protocol population. There was no indication that comorbidities or
malnutrition adversely affected outcomes. The key study limitation was that postbaseline
clinical biochemistry was only evaluated when clinically indicated.
Conclusions
Pyronaridine–artesunate had good tolerability and effectiveness in a representative African
population under conditions similar to everyday clinical practice. These findings support
pyronaridine–artesunate as an operationally useful addition to the management of acute
uncomplicated malaria.
Trial registration
ClinicalTrials.gov NCT03201770.
Author summary
Why was this study done?
• Pyronaridine–artesunate has shown high efficacy and an acceptable safety profile in ran-
domized controlled clinical trials for the treatment of acute uncomplicated Plasmodium
falciparum malaria.
• Transient, asymptomatic, mostly mild-to-moderate increases in liver aminotransferases
have been observed with pyronaridine–artesunate in some patients.
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• We assessed pyronaridine–artesunate hepatic safety, tolerability, and effectiveness in
adults and children for the treatment of acute uncomplicated malaria under real-world
conditions in Africa, including patients with elevated baseline liver aminotransferases.
What did the researchers do and find?
• In a single-arm, open-label, cohort event monitoring study conducted across 5 African
countries, patients of any age, weighing >5 kg with acute uncomplicated malaria
received fixed-dose pyronaridine–artesunate once daily for 3 days.
• Patient exclusion and inclusion criteria were consistent with the approved prescribing
information, and patients with elevated baseline liver enzymes could be treated under
the protocol.
• The study included 8,560 malaria episodes, 158 of which occurred in patients with base-
line alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
abnormalities.
• There were no hepatic events following pyronaridine–artesunate treatment. Tolerability
was as reported in previous studies, and treatment effectiveness at day 28 was 98.6% in
patients with acute uncomplicated P. falciparum malaria.
What do these findings mean?
• Pyronaridine–artesunate was an operationally effective and well-tolerated antimalarial
therapy in this unselected population of patients from 5 African countries.
Introduction
Africa carries the greatest malaria burden, with an estimated 215 million cases in 2019 and
94% of global deaths, mainly in children [1]. Children are also most vulnerable to ongoing
morbidity, particularly from severe anemia [2].
Artemisinin-based combination therapy (ACT) is recommended for first-line therapy of
acute uncomplicated malaria, with several artemisinin and partner drug combinations
deployed worldwide. Artemisinin-resistant Plasmodium falciparum are established in South-
east Asia, and where these strains are also resistant to partner drugs, high clinical failure rates
are reported [3]. De novo Kelch 13 artemisinin resistance mutations have been verified in
Africa [4], and parasites will eventually overcome the effectiveness of the most widely used
therapies [5].
Pyronaridine–artesunate has demonstrated high efficacy in acute uncomplicated malaria in
both Africa and Asia [6–18], including against artemisinin-resistant P. falciparum [7–10]. In
controlled clinical trials, pyronaridine–artesunate safety compared favorably with other anti-
malarial drugs [6,11,14]. Asymptomatic, transient, mild-to-moderate elevations in alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) occurred in some patients
treated with pyronaridine–artesunate [6,11,14]. A systematic meta-analysis showed that fol-
lowing first treatment, the risk of ALT greater than 5 times the upper limit of normal
(>5×ULN) was higher in those treated with pyronaridine–artesunate (0.7%) compared to
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standard deviation; STROBE, Strengthening the
Reporting of Observational Studies in
Epidemiology; ULN, upper limit of normal.
comparators (0.2%; relative risk [RR] 3.34 [95% confidence interval CI 1.63, 6.84]), but there
was no difference in the proportion of patients with elevated AST>5×ULN (RR 1.80 [95% CI
0.89, 3.65]), or increased bilirubin >2.5×ULN (RR 1.03 [95% CI 0.49, 2.18]) [6]. Although 1
case of raised ALT with raised bilirubin was reported, there were no reports of severe drug-
induced liver injury, and no clinical observations indicative of hepatic injury with pyronari-
dine–artesunate [6,11,14]. Subsequently, an extensive longitudinal study in West African
malaria patients indicated no increased risk of biochemically defined hepatic dysfunction on
repeated pyronaridine–artesunate treatment [11]. In that study, the incidence of ALT or AST
>3×ULN and total bilirubin >2×ULN was 0.31% (3/967) with artemether–lumefantrine,
0.22% (3/1,342) with pyronaridine–artesunate, 0.15% (2/1,340) with dihydroartemisinin–
piperaquine, and 0.09% (1/1,061) with artesunate–amodiaquine [11]. Similar to previous stud-
ies, the elevations in ALT/AST occurred in the first 7 days after treatment with pyronaridine–
artesunate and generally had normalized by day 15. The liver enzyme observations were not
associated with any clinical signs or symptoms of hepatic injury and were without sequelae or
the need for any intervention [11].
Although the clinical relevance of the observed transient asymptomatic liver aminotransfer-
ase elevations is unclear, all pyronaridine–artesunate clinical trial populations to date have
excluded patients with underlying hepatic dysfunction. Consequently, it is currently unknown
if underlying hepatic dysfunction will progress to clinical manifestations of liver impairment
with pyronaridine–artesunate. It is important, therefore, to clarify the risk–benefit of pyronari-
dine–artesunate in an unselected, representative population treated under normal clinical con-
ditions in accordance with current drug prescribing recommendations.
This large clinical trial was conducted as part of the postmarketing requirements specified
by the European Medicines Agency (EMA) for pyronaridine–artesunate. The pyronaridine–
artesunate-approved product prescribing information does not require prior measurement of
liver enzymes before treatment [19]. The primary aim of the study was to assess the incidence
of clinical hepatic signs and symptoms in patients recruited in a normal clinical context,
including patients with baseline elevations in ALT/AST. Any potential differences in the inci-
dence of clinical hepatic events in malaria patients with elevated baseline ALT/AST values
were to be compared to a matched cohort with normal values. The EMA considered the proto-
col appropriate to answer the question of whether clinically relevant hepatic events occurred
following pyronaridine–artesunate in patients recruited as per the summary of product char-
acteristics (i.e., a clinically relevant population) [19]. The study encompassed active pharma-
covigilance alongside launch and scale-up of pyronaridine–artesunate deployment in Africa
and was designed in accordance with standard cohort event monitoring protocols [20,21].
In summary, the aim of this study was to characterize pyronaridine–artesunate hepatic
safety, tolerability, and effectiveness in a real-world setting in a clinically relevant population
across a network of representative study sites in Central and West Africa.
Methods
Study design
This single-arm, open-label cohort event monitoring study was conducted at 6 health centers
in Cameroon, Democratic Republic of Congo, Gabon, Ivory Coast, and Republic of Congo
between 22 June 2017 and 10 April 2019. The protocol adhered to Good Clinical Practice, the
Declaration of Helsinki, and relevant regulations in the respective countries and was reviewed
and accepted as a valid postmarketing safety assessment by the EMA. The authors vouch for
the accuracy and completeness of the data and the fidelity of the trial conduct, analysis, and
reporting to the protocol. A copy of the protocol and statistical analysis plan is provided in the
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Supporting information (S1 Protocol and SAP). This study is reported as per the Strengthen-
ing the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 STROBE
Checklist).
Ethics statement
All patients, or their parents/guardians, provided written informed consent, and children able
to understand the study gave signed assent. The protocol was conducted in compliance with
the Declaration of Helsinki (amended Tokyo 2004) and the directives in the respective coun-
tries, in particular concerning the submission to Ethics Committees and the protection of per-
sonal data. Additionally, the study was conducted in accordance with the principles of the
Good Clinical Practice according to the International Council for Harmonization (ICH) Har-
monized Tripartite Guidance (CPMP/ICH/135/95). The ethics committee at each study site
granted ethical approval as follows. Cameroon: Comité National d’Ethique de la Recherche
pour la Santé Humaine; Democratic Republic of Congo: Comité d’Ethique de l’Université Pro-
testante au Congo; Gabon: Comité Nationale d’Ethique et de la Recherche Scientifique and
Comité d’Ethique Institutionnel Albert Schweitzer Hospital, Lambaréné; Ivory Coast: Comité
Nationale d’Ethique et de la Recherche Scientifique and Comité National d’Ethique des Sci-
ences de la Vie et de Santé; and Republic of Congo: Institutional Ethics Committee of the Fon-
dation Congolaise pour la Recherche Médicale.
Patients
Eligible patients were male or female, of any age, with body weight of at least 5 kg. All patients
had acute uncomplicated malaria and a fever or history of fever within the previous 24 hours
and/or anemia. Exclusion criteria were severe malaria, clinical signs or symptoms of hepatic
injury (nausea and abdominal pain associated with jaundice), known severe liver disease (i.e.,
decompensated cirrhosis, Child–Pugh stage C or D), known allergy to artemisinin and/or pyr-
onaridine, known pregnancy, lactation, treatment with pyronaridine–artesunate in the previ-
ous 28 days, or if the patient was considered by the investigator to be at particular risk.
Treatment
Fixed-dose pyronaridine–artesunate (Shin Poong Pharmaceutical, Seoul, South Korea) was
administered once daily for 3 days with 2 formulations provided according to body weight and
without regard to food intake. Daily doses for pyronaridine–artesunate tablets (180:60 mg)
were 1 (�20 to<24 kg), 2 (�24 to<45 kg), 3 (�45 to<65 kg), or 4 (�65 kg); and for granule
sachets (60:20 mg) were 1 (�5 to<8 kg), 2 (�8 to<15 kg), or 3 (�15 to<20 kg). To reflect
real-world practice, patients could be included more than once in the study, following a
28-day washout period between consecutive pyronaridine–artesunate treatments. Patients
received the first pyronaridine–artesunate dose under supervision and were provided with the
remaining doses to be taken unsupervised on the subsequent 2 consecutive days.
Procedures
At enrollment on day 0, eligible patients underwent physical examination, with demographic
data and medical history noted.
Blood samples (5 mL) were collected for hematology, clinical chemistry, and confirmation
of malaria diagnosis. Blood samples were stored for retrospective analysis of baseline clinical
chemistry and viral hepatitis assessment: hepatitis A, B, C, and E (anti-HAV IgM, anti-HBc
IgM, HBsAg, hepatitis C RNA, and hepatitis E IgM antibody) and hepatitis delta antibody if
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positive for hepatitis B. All laboratory analysis was performed at the site where the patient was
recruited by technically certified staff, and results were validated by external independent labo-
ratories. Standard quality control procedures were in place, including daily internal controls
and the quality control process assessed by the clinical monitors.
Malaria was diagnosed using a rapid diagnostic test (RDT) or Giemsa-stained thick blood
smear. The RDT was consistent with local treatment guidelines and used according to the
manufacturer’s instructions by staff trained according to the local standard operating proce-
dure (S1 Methods). Microscopic diagnosis was performed in accordance with standard proto-
cols by qualified microscopists [22], with 10% of slides undergoing quality control checks by
an independent microscopist. Blood spots were obtained at screening and stored on filter
paper for polymerase chain reaction (PCR) genotyping. Patients were visited by a community
health worker (CHW) on days 7 and 28 who inquired regarding any signs or symptoms of
malaria. In addition, patients were requested to present to the health center should they have
malaria symptoms at any time during follow-up. Any patient who presented with suspected
malaria was clinically examined and malaria confirmed by microscopy. At follow-up day 28,
blood samples were collected from all patients to confirm parasite clearance by microscopy. In
the case of P. falciparum recurrence, PCR genotyping was used to differentiate between recru-
descence and reinfection by comparing blood spot samples taken at baseline versus recurrence,
using published criteria [23].
Adverse events were assessed without knowledge of baseline ALT/AST. Patients were to
present at the clinic should any adverse event occur within 28 days of pyronaridine–artesunate
dosing. Home follow-up visits were conducted by CHWs on days 7 and 28 to assess treatment
adherence, clinical condition, adverse events, and concomitant medications. CHWs were
trained before the study and retrained during the study by clinical investigators in the assess-
ment of safety and tolerability using questionnaire forms. In addition, investigators accompa-
nied CHWs to field visits to assure quality and consistency in adverse event assessment. All
clinical information provided by CHWs was assessed by clinical investigators to ensure accu-
rate medical recording of all safety and tolerability signs. CHWs were provided with pictorial
information specifically identifying the signs and symptoms of liver injury. Furthermore, any
potential hepatotoxic signs or symptoms noted by CHWs were specifically discussed with the
study doctor, with patients referred to the clinic if necessary.
Hepatic events prompted blood sampling for clinical chemistry and hematology and a full
hepatitis panel. Assessment at the health facility was triggered by serious or severe adverse
events or adverse events of special interest, i.e., hepatotoxicity (jaundice, dark urine, putty/
mastic stool, worsening of fatigue, nausea, vomiting, anorexia, abdominal pain, itching, rash,
spontaneous bruising, or appearance of red spots), serious liver reactions, and hypersensitivity
(flushing, wheals/urticaria, breathlessness, faintness, or a fall in blood pressure). Female partic-
ipants had a urinary pregnancy test at day 28, with provision in the case of pregnancy for
extended follow-up until the birth or other outcome.
Outcomes and trial populations
The safety population included all enrolled patients who received at least 1 dose of study medi-
cation for any malaria episode. The primary outcome was the incidence of hepatic events in
the safety population following pyronaridine–artesunate treatment of malaria patients with
baseline ALT or AST>2×ULN, defined as clinical signs and symptoms of possible hepatotox-
icity, i.e., fatigue, nausea, abdominal pain, itching, or signs of jaundice (dark urine, putty or
mastic colored stools, and yellowing of the whites of the eyes or skin), associated with a rise in
ALT/AST >2× the baseline value.
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Safety outcomes were the incidence of adverse events in the safety population overall and
categorized by normal/abnormal/unknown baseline ALT/AST, any underlying hepatic disease
identified on the hepatitis panel, HIV status (where known), age, sex, weight, and nutritional
status. Malnutrition was defined for patients <5 years old as a mid-upper arm circumference
<115 mm, in patients aged�5 years to�19 years using the World Health Organization age-
and sex-specific body mass index (BMI)-for-age z-scores [24], and for adults>19 years old as
a BMI <18.5 kg/m2.
Treatment adherence was self-assessed by patients and also estimated by CHWs based on
empty packaging provided by patients versus the number of tablets/sachets dispensed.
Effectiveness was evaluated on day 28 in the intention-to-treat and per-protocol popula-
tions, with cure defined as the absence of microbiologically confirmed malaria without previ-
ous failure. Cure rates were reported unadjusted and PCR adjusted for P. falciparum
reinfection. Day 28 effectiveness subgroup analysis was planned for by country, dosing (gran-
ules versus tablets), malnutrition, and age. Additional outcomes were time between malaria
episodes and the frequency of repeat episodes. The intention-to-treat population included all
malaria episodes treated with at least 1 dose of study medication with confirmed positive para-
sitemia at baseline. The per-protocol population included all malaria episodes in the intention-
to-treat population in patients who were treated with a full course of study medication (adher-
ence per patient self-assessment), had a day 28 effectiveness endpoint, did not vomit after
study drug administration (except where vomiting occurred after the first dose and dosing was
successfully repeated), and who had no prior or concomitant medication, which had an anti-
malarial effect and so could interfere with the treatment outcome. All outcomes and trial pop-
ulations were prespecified (S1 Protocol and SAP).
Statistical analysis
Sample size was calculated based on the primary objective, i.e., the incidence of protocol-defined
hepatic events in malaria patients with baseline ALT/AST>2×ULN. The screening rate in previ-
ous studies for malaria patients with baseline ALT/AST>2×ULN was 1.4% [25]. To detect 1
protocol-defined hepatic event in patients with baseline ALT/AST>2×ULN with a probability
of at least 80% (81.6%), 120 malaria episodes occurring in patients with a baseline ALT/AST
value>2×ULN were required. Thus, to observe 1 severe hepatic event, at least 8,572 malaria epi-
sodes were required (i.e., 1.4% of 8,572 = 120). There was no country-specific recruitment target,
and the trial was to continue until observation of at least 120 malaria episodes in patients with
elevated baseline ALT/AST. As a secondary endpoint, a multivariate logistic regression model
was planned in order to compare the incidence of hepatic events in patients with elevated base-
line ALT/AST values versus those with normal values. However, as the primary endpoint did
not occur in any patient during the trial, this analysis was not conducted.
Descriptive statistics were used for analysis of all other outcomes, with 95% CIs calculated
(Clopper–Pearson). To better mimic the clinical reality, patients could be included more than
once in the study. For the outcome of clinical effectiveness, each malaria episode was treated as
an independent event, with no adjustment for repeated measures. This was to better reflect the
endpoint of operational effectiveness, i.e., to include patient-related as well as drug-related
contributors and to be consistent with previous analyses of randomized controlled trials of
repeated treatment with pyronaridine–artesunate [11,25]. For the determination of cure rates,
patients with a missing parasitological assessment at day 28 were considered as failures in the
intention-to-treat population and excluded from the per-protocol population. For further
details, please see S1 Protocol and SAP. Statistical analysis used SAS (version 8.2) and Graph-
Pad Prism (version 8.4.3). Adverse events were coded using MedDRA (version 22).
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Results
Patients
Of the 8,609 malaria episodes that met study eligibility criteria, 8,560 were treated with at least
1 dose of study medication, comprising the safety population (Fig 1). Of the 1.9% (158/8,560)
of malaria episodes occurring in patients with baseline ALT/AST elevations >2×ULN, 19.0%
(30/158) were positive for viral hepatitis. The safety population included similar proportions
of males and females; most patients had 1 malaria episode, but the maximum was 9 episodes
Fig 1. Screening and analysis populations. There may have been more than 1 reason for exclusion from enrollment
into the study or exclusion from a study population. Normal LFTs were ALT or AST�2×ULN and abnormal values
were ALT or AST>2×ULN at baseline. “Patient considered to be at risk from participation” included patients that
investigators considered inappropriate for trial inclusion, mainly because of low hemoglobin or an inability to draw
blood for assessments. Note that no patient with clinically evident preexisting liver injury was excluded from the
screening population. ALT, alanine aminotransferase; AST, aspartate aminotransferase; LFT, liver function test; ULN,
upper limit of normal.
https://doi.org/10.1371/journal.pmed.1003669.g001
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(Table 1). Repeated malaria episodes accounted for 16.7% (1,414/8,480) of all episodes in the
intention-to-treat population (Table 1). Time between repeated malaria episodes tended to
decrease for each subsequent episode (S1 Fig). Based on patient self-assessment, treatment
adherence was achieved in 94.5% (8,085/8,560) of malaria episodes versus 81.5% (6,974/8,560)
based on empty medication packaging presented to CHWs (Table 1).
Hepatic safety
There were no malaria episodes with protocol-defined hepatic events in any patient in the
safety population. No further planned secondary analyses of the primary endpoint could,
therefore, be conducted.
Safety
Adverse events of any cause occurred in 20.8% (1,490/7,154) of patients, most frequently
pyrexia (5.1% [366/7,154]) and vomiting (4.2% [303/7,154]) (Table 2, S1 Table). There was no
difference in adverse event frequency between patients with normal versus abnormal baseline
ALT/AST values (Fig 2), although those with unknown ALT/AST values experienced more
adverse events (40.0% [14/35] 95% CI, 25.6 to 56.4).
Adverse event frequency was not affected by sex, weight, nutritional status, HIV status, or
first versus repeated malaria episode (Fig 2). The nature of adverse events and their incidence
was comparable for first versus repeated episodes (S2 Table). Four of the 30 patients positive
for viral hepatitis had adverse events (13.3%).
Higher adverse event rates were noted for patients aged under 1 year (29.1% [39/134] 95%
CI, 21.6 to 37.6) and those�18 years of age (27.0% [459/1,700] 95% CI, 24.9 to 29.2) versus
those aged 5 to<18 years (16.9% [611/3,609] 95% CI, 15.7 to 18.2) (Fig 2, S3 and S4 Tables).
In particular, vomiting was associated with age, occurring in 11.2% [15/134] of children under
1 year old, 7.7% (131/1,711) of those aged 1 to<5 years, 3.1% (112/3,609) of children and ado-
lescents 5 years to 18 years, and in just 2.8% (47/1,700) of adults (S3 Table). The frequency of
pyrexia and cough also tended to decrease with increasing age (S3 Table).
There were 9.6% (685/7,154) of patients with adverse events considered related to pyronari-
dine–artesunate treatment, most commonly vomiting (3.2% [228/7,154]) and headache (1.0%
[72/7,154]) (S5 Table). Treatment was discontinued early owing to adverse events in 0.8% (54/
7,154) of patients, mostly because of vomiting (0.5% [37/7,154]) (S6 Table). Severe adverse
events occurred in 0.4% (32/7,154) of patients and life-threatening events in 0.1% (10/7,154)
(S7 Table).
Serious adverse events were reported in 0.4% (29/7,154) of patients, with the most frequent
being malaria (0.1% [9/7,154]) and anemia (0.1% [7/7,154]) (S8 Table). Four patients had seri-
ous adverse events considered possibly related to pyronaridine–artesunate treatment (epi-
staxis, gastroenteritis, and 2 cases of anemia).
There were 3 deaths during the study (diarrhea, drowning, and severe malaria), none of
which were considered related to pyronaridine–artesunate treatment. The case of severe
malaria occurred in a 6-year-old girl from the Democratic Republic of Congo who was
enrolled with acute uncomplicated malaria, presenting with asthenia and vomiting. She was
diagnosed with severe malaria 1.5 hours following the first dose of pyronaridine–artesunate
and admitted to hospital after symptoms of asthenia worsened. Pyronaridine–artesunate was
discontinued, and the patient treated with intravenous quinine. She also received intravenous
phenobarbital and diazepam for convulsions and cefotaxime and gentamycin for suspected
meningitis, but her condition rapidly worsened, and she unfortunately died later the same day.
As the patient died of severe malaria within 24 hours of her first dose of pyronaridine–
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Table 1. Baseline demographic and clinical characteristics in the safety population.
Characteristic by patient Normal baseline ALT/AST
(N = 6,961)
Abnormal baseline ALT/AST
(N = 158)
Unknown baseline ALT/AST
(N = 35)
Total (N = 7,154)
Male sex—no. (%) 3,461 (49.7) 89 (56.3) 19 (54.3) 3,569 (49.9)
Mean age (SD)—y 14.0 ± 14.6 9.3 ± 13.6 10.8 ± 13.0 13.9 ± 14.6
<1 y—no. (%) 124 (1.8) 9 (5.7) 1 (2.9) 134 (1.9)
�1 y to <5 y—no. (%) 1,621 (23.3) 77 (48.7) 13 (37.1) 1,711 (23.9)
�5 to <18 y—no. (%) 3,543 (50.9) 51 (32.3) 15 (42.9) 3,609 (50.4)
�18 y—no. (%) 1,673 (24.0) 21 (13.3) 6 (17.1) 1,700 (23.8)
Mean body weight (SD)—kg 33.1 ± 20.9 23.5 ± 17.8 26.0 ± 19.4 32.8 ± 20.9
�5 to <20 kg—no. (%) 2,517 (36.2) 97 (61.4) 20 (57.1) 2,634 (36.8)
�20 kg—no. (%) 4,444 (63.8) 61 (38.6) 15 (42.9) 4,520 (63.2)
Malnourished—no. (%) 365 (5.2) 3 (1.9) 2 (5.7) 370 (5.2)
Nonmalnourished—no. (%) 6,596 (94.8) 155 (98.1) 33 (94.3) 6,784 (94.8)
Country—no. (%)
Ivory Coast 1,200 (17.2) 14 (8.9) 1 (2.9) 1,215 (17.0)
Cameroon 776 (11.1) 20 (12.7) 1 (2.9) 797 (11.1)
Democratic Republic of Congo 2,785 (40.0) 64 (40.5) 10 (28.6) 2,859 (40.0)
Republic of Congo 607 (8.7) 23 (14.6) 5 (14.3) 635 (8.9)
Gabon 1,593 (22.9) 37 (23.4) 18 (51.4) 1,648 (23.0)
Number of malaria episodes per patient—no. (%)
1 5,885 (84.5) 130 (82.3) 22 (62.9) 6,037 (84.4)
2 811 (11.7) 17 (10.8) 12 (34.3) 840 (11.7)
3 162 (2.3) 6 (3.8) 1 (2.9) 169 (2.4)
4 71 (1.0) 4 (2.5) 0 75 (1.0)
5 20 (0.3) 1 (0.6) 0 21 (0.3)
6 7 (0.1) 0 0 7 (0.1)
7 3 (<0.1) 0 0 3 (<0.1)
8 1 (<0.1) 0 0 1 (<0.1)
9 1 (<0.1) 0 0 1 (<0.1)
Characteristic by malaria episode Normal baseline ALT/AST
(N = 8,367)
Abnormal baseline ALT/AST
(N = 158)
Unknown baseline ALT/AST
(N = 35)
Total (N = 8,560)
Mean baseline ALT (SD) [range]—IU/L 12.8 (8.2) [0.1, 95.0] 100.7 (146.4) [1.8, 1,103.4] – 14.4 (24.5)a
[0.1, 1,103.4]
Mean baseline AST (SD) [range]—IU/L 28.7 (12.2) [1.0, 163.0] 182.6 (271.4)b [20.0, 1,952.3] – 31.5 (43.9)c
[1.0, 1,952.3]
Episodes in which first dose was vomited—no. (%) 199 (2.4) 5 (3.2) 10 (28.6) 214 (2.5)
Episodes that received a repeated first dose—no. (%) 189 (2.3) 5 (3.2) 10 (28.6) 204 (2.4)
Patient-reported adherence—no. (%) 7,925 (94.7) 145 (91.8) 15 (42.9) 8,085 (94.5)
Adherence assessed by CHWs—no. (%)d 6,837 (81.7) 126 (79.7) 11 (31.4) 6,974 (81.5)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHW, community health worker; LFT, liver function test; SD, standard deviation; ULN, upper limit of
normal.
Normal LFTs were ALT or AST�2×ULN, and abnormal values were AST or ALT >2×ULN at baseline. –, no observations.
aN = 8,525.
bN = 157.
cN = 8,524.
dAdherence was assessed by CHWs based on the number of empty blisters/sachets presented.
https://doi.org/10.1371/journal.pmed.1003669.t001
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artesunate, it is usual to consider the cause as disease progression, and so the death was not
attributed to drug treatment. The death from diarrhea occurred in a 66-year-old man who
received 6 pyronaridine–artesunate tablets over 3 days, who died 29 days after the first dose of
study medication from severe diarrhea, with no further information available. The other death
was that of a 9-year-old boy who drowned in a river 12 days after the first administration of
pyronaridine–artesunate.
An adverse event of special interest occurred in 9 patients (0.1%, N = 7,154); in all cases,
this was hypersensitivity occurring only in 1 episode: 6 occurred in the first episode (6/7,085;
0.09% 95% CI, 0.03 to 0.18), and the other 3 occurred for the first time in episodes 2, 3, and 4,
respectively (3/1,051; 0.3%; 95% CI, 0.06 to 0.8). All patients were aged�5 years with normal
baseline ALT/AST, 4 had urticaria, and 1 each had maculo-papular rash, papular rash, hyper-
sensitivity (symptomatology of flushing and wheals), lip swelling, and eye pruritis; all were of
mild-to-moderate intensity.
CHWs identified 595 cases that required discussion of adverse events with the investiga-
tional site, with 165 referrals. An additional 223 cases self-referred. Of these, further blood
Table 2. Most common adverse events of any cause in patients treated with pyronaridine–artesunate for acute uncomplicated malaria (safety population).
Adverse event, n (%) Normal baseline ALT/AST
(N = 6,961)
Abnormal baseline ALT/AST
(N = 158)
Unknown baseline ALT/AST
(N = 35)
Total (N = 7,154)
Patients with any adverse event 1,449 (20.8) 27 (17.1) 14 (40.0) 1,490 (20.8)
Pyrexia 361 (5.2) 4 (2.5) 1 (2.9) 366 (5.1)
Vomiting 285 (4.1) 8 (5.1) 10 (28.6) 303 (4.2)
Headache 201 (2.9) 0 1 (2.9) 202 (2.8)
Cough 100 (1.4) 3 (1.9) 3 (1.9) 103 (1.4)
Diarrhea 79 (1.1) 2 (1.3) 0 81 (1.1)
Abdominal pain 74 (1.1) 0 0 74 (1.0)
Dizziness 65 (0.9) 0 0 65 (0.9)
Fatigue 65 (0.9) 0 0 65 (0.9)
Asthenia 48 (0.7) 1 (0.6) 0 49 (0.7)
Influenza 43 (0.6) 3 (1.9) 0 46 (0.6)
Decreased appetite 42 (0.6) 0 0 42 (0.6)
Influenza-like illness 40 (0.6) 1 (0.6) 0 41 (0.6)
Pruritus 40 (0.6) 0 0 40 (0.6)
Anemia 26 (0.4) 1 (0.6) 2 (5.7) 29 (0.4)
Nausea 31 (0.4) 0 0 31 (0.4)
Rhinorrhea 23 (0.3) 0 0 23 (0.3)
Malaria 16 (0.2) 1 (0.6) 1 (2.9) 18 (0.3)
Rash 22 (0.3) 0 0 22 (0.3)
Vertigo 17 (0.2) 0 0 17 (0.2)
Arthralgia 16 (0.2) 0 0 16 (0.2)
Abdominal pain upper 14 (0.2) 0 0 14 (0.2)
Acarodermatitis 13 (0.2) 0 1 (2.9) 14 (0.2)
Nasopharyngitis 12 (0.2) 0 0 12 (0.2)
Myalgia 12 (0.2) 0 0 12 (0.2)
Hyperhidrosis 12 (0.2) 0 0 12 (0.2)
Bronchitis 11 (0.2) 0 0 11 (0.2)
Adverse events occurring in >0.1% of patients; a complete list of adverse events is shown in S1 Table. Patients may have had more than 1 adverse event. Normal LFTs
were ALT or AST�2×ULN, and abnormal values were AST or ALT >2×ULN at baseline.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LFT, liver function test; ULN, upper limit of normal.
https://doi.org/10.1371/journal.pmed.1003669.t002
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testing was clinically indicated in 7 patients, with no concerning results (S9 Table). Eleven
pregnancies were confirmed during the study. Three were terminated for social reasons. The
remaining 8 (6 of which were exposed to study treatment during the first trimester) progressed
normally with spontaneous deliveries, except for 1 case of uterine hypertonus at full term,
requiring cesarean section.
Effectiveness
P. falciparum was the predominant pathogen, present in 8,478 of 8,480 malaria episodes
(intention-to-treat population). Plasmodium ovale (n = 70) and Plasmodium malariae (n = 55)
occurred as mixed Plasmodium infections; 1 P. ovale/P. malariae coinfection and 1
Fig 2. Frequency of adverse events of any cause subgroup analysis in the safety population. Data are shown for the number of patients.
Patients may have been categorized differently for different malaria episodes. Categorical data were not available for all patients. ALT, alanine
aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; LFT, liver function test.
https://doi.org/10.1371/journal.pmed.1003669.g002
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Plasmodium vivax mono-infection were identified (S10 Table). Adjusting for P. falciparum
reinfection, treatment effectiveness at day 28 was 98.6% ([7,369/7,746] 95% CI 98.3 to 98.9) in
the per-protocol population and 90.9% ([7,705/8,478] 95% CI 90.2 to 91.5) in the intention-to-
treat population. The unadjusted cure rate in the per-protocol population was 93.2% ([7,221/
7,746] 95% CI 92.6 to 93.8) and 85.9% ([7,285/8,480] 95% CI 85.1 to 86.6) in the intention-to-
treat population (S11 Table).
Subgroup analyses of the day 28 PCR-adjusted cure rate in the per-protocol population are
shown in Fig 3 and S11 Table. Cure rates across the 5 participating countries exceeded 98%.
The cure rate was lower for the granule formulation (97.4% [2,849/2,925] 95% CI 96.8 to 97.9)
versus tablets (99.4% [4,790/4,821] 95% CI 99.1 to 99.6) and lower in infants (<1 year old;
96.9% [126/130] 95% CI, 92.3 to 99.2) versus older children and adults (98.6% [7,513/7,616]
95% CI, 98.4 to 98.9), though CIs overlapped. In malnourished patients, the cure rate was
100% (370/370).
Discussion
This study was conducted within the Central Africa Network on Tuberculosis, HIV/AIDS,
and Malaria (CANTAM). There were no hepatic events in 8,560 episodes of uncomplicated
Fig 3. Day 28 PCR-adjusted treatment effectiveness in the per-protocol population subgroup analysis. Data are shown for the number of malaria
episodes. CI, confidence interval; PCR, polymerase chain reaction.
https://doi.org/10.1371/journal.pmed.1003669.g003
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P. falciparum malaria treated with pyronaridine–artesunate, 158 of which occurred in patients
with baseline ALT or AST abnormalities. Tolerability was consistent with previous studies,
and treatment effectiveness at day 28 was 98.6%.
Pyronaridine–artesunate efficacy and safety have been already demonstrated in multicen-
ter, randomized, controlled clinical trials conducted for regulatory purposes in a selected
patient population. In those studies, raised ALT >5×ULN was more frequently observed with
pyronaridine–artesunate versus comparators, but clinical signs and symptoms of hepatotoxic-
ity were not manifest and all patients recovered without sequelae or intervention [6,11,14–
18,25]. However, the exclusion from these Phase II/III trials of individuals with elevated base-
line liver enzymes left uncertainty regarding the clinical relevance of the biochemical findings
in patients with underlying hepatic dysfunction. The aim of the current study was to generate
data to inform clinical practice and provide evidence for decision-making by Ministries of
Health and malaria control programs. Additionally, the study was conducted following EMA
requirements to collect safety data to support scale-up of pyronaridine–artesunate access in
countries where routine pharmacovigilance is limited. Thus, the design reflected the reality of
malaria treatment in Central and West Africa to investigate pyronaridine–artesunate as an
operational antimalarial. The study protocol specified a patient population based on the
approved prescribing information for pyronaridine–artesunate and so can be considered rep-
resentative of the wider patient population that might be treated with the drug. Patients under-
went prescreening procedures consistent with those conducted under normal clinical practice.
Although samples for clinical biochemistry were taken at baseline, these were only available
retrospectively and collected to verify that patients with elevated ALT and AST had actually
been recruited in sufficient numbers to provide the necessary power for the primary analysis
of protocol-defined hepatic event incidence. Of the 8,560 malaria episodes followed, 1.9%
(158) occurred in patients with baseline ALT/AST elevations >2×ULN. In fact, no hepatic
events occurred in any patient, and the study exceeded the recruitment target, demonstrating
with 89.2% power that none of 158 patients with elevated baseline ALT/AST experienced a
protocol-defined hepatic event.
There are some key limitations to this study as designed. Firstly, this study aimed to assess
whether there was any clinical evidence of hepatotoxicity following pyronaridine–artesunate
administration according to the approved prescribing information. There is no requirement to
measure ALT/AST in patients without signs or symptoms of liver dysfunction prior to treat-
ment in normal clinical practice. Thus, the current study was explicitly designed to identify
clinical hepatic events only. Although this reflects normal practice and resource availability in
the study setting, not all patients with hepatitis will manifest clinical symptoms, and our study
does not exclude the possibility of occurrences of subclinical liver injury. The use of the retro-
spective analysis of baseline blood samples was employed to confirm that patients with AST/
ALT>2×ULN had, in fact, been recruited and to allow comparison with a matched cohort of
patients with normal baseline ALT/AST (secondary endpoint). Postbaseline clinical biochem-
istry was only conducted where clinically indicated, for example, for biochemical confirmation
of any clinically suspected signs of hepatotoxicity. In fact, postbaseline biochemistry for any
reason was indicated in only 7 patients. Consequently, no conclusions can be drawn on the
impact of pyronaridine–artesunate on postbaseline ALT/AST levels for patients with elevated
baseline values. Secondly, in line with the prescribing information for pyronaridine–artesu-
nate, patients with clinical signs or symptoms of hepatic injury (such as nausea and/or abdom-
inal pain associated with jaundice) or known severe liver disease (i.e., decompensated
cirrhosis, Child–Pugh stage B or C) were excluded [19]. Thus, no conclusions can be reached
regarding the safety of pyronaridine–artesunate in patients with preexisting severe liver injury,
and ethical considerations preclude the evaluation of patients in clinical trials who have
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contraindications to treatment. In fact, although the prespecified exclusion criteria are easily
recognized in normal clinical practice, no patients were excluded from the study for hepatic
injury or severe liver disease. This is probably because malaria tends to occur in younger
patients, and the preexisting liver disease must be severe enough to be clinically evident. One
further limitation is that because there were no instances of the primary endpoint, i.e., proto-
col-defined hepatic events, a number of the planned secondary analyses could not be con-
ducted, most notably the cohort comparison with patients who had normal baseline ALT/AST
[20] and a sub-analysis of the potential influence of concomitant medications on the incidence
of hepatic events (S1 Protocol and SAP).
Randomized controlled clinical trials of pyronaridine–artesunate provide an extensive
safety database compared to a number of different antimalarial drugs, and the safety profile is
well documented [6,11,14–18,25]. However, previous study populations were selected using
more restrictive inclusion and exclusion criteria and had extensive follow-up and clinical mon-
itoring. Safety and tolerability assessed under real-world clinical conditions in a clinically rele-
vant population provide a valuable assessment of risk–benefit for prescribers and patients,
particularly where pharmacovigilance is limited [20,21]. In the current study, only 0.8% (54/
7,154) of patients discontinued treatment owing to an adverse event. Adverse event frequency
(20.8% [1,490/7,154]) was lower than observed in previous randomized controlled clinical tri-
als (56.5% [2,348/4,157]), as was the frequency of serious adverse events (0.4% [29/7,154] ver-
sus 1.0% [41/4,157]) [11,14]. This is explained by less frequent follow-up (days 7 and 28) in the
current study than in the previous trials (days 1 to 3, 7, 14, 21, and 28). Also, postbaseline
hematological and biochemical data were not routinely collected, so out-of-normal range val-
ues without clinical symptoms were not captured. Adverse event frequency was lower in
patients aged�5 to 18 years than in younger children, mainly because of more frequent vomit-
ing and pyrexia in children <1 year old. A similar pattern was observed in a previous study
conducted in West Africa [11]. Another similarity between these 2 studies is that the frequency
of adverse events tended to decrease on malaria retreatment [11]. Overall, the most common
adverse events observed were consistent with previous studies and with the symptoms of
malaria, and there were no unexpected adverse events based on the known safety profile of
pyronaridine–artesunate [6,11,14–18,25].
The pharmacodynamic outcome of this trial was clinical effectiveness under real-world
conditions, whereas previous randomized clinical trials reported clinical efficacy as defined
using the standard WHO outcome of adequate clinical and parasitological response (ACPR)
[22]. Across all 5 countries included in the study, pyronaridine–artesunate treatment effective-
ness was�98%. This assessment was based on the per-protocol population, which included
patients with adherence assessed from patient reporting, rather than the lower adherence rates
reported by CHWs. Thus, the clinical effectiveness of pyronaridine–artesunate might be
expected to be lower than its efficacy following fully supervised therapy in randomized clinical
trials. However, this was not the case. Overall effectiveness with the tablet formulation in the
per-protocol population, adjusted for reinfection by PCR, was 99.3% (4,790/4,821] 95% CI
99.1 to 99.6) and was comparable with>99% ACPR reported in randomized controlled clini-
cal trials using this formulation [11,14,15,18]. Effectiveness of the pyronaridine–artesunate
pediatric granule formulation was lower (97.4% [2,849/2,925] 95% CI 96.8 to 97.9) than for the
tablet formulation, but comparable with ACPR reported from a previous randomized con-
trolled trial in African children using the granule formulation (97.1% [329/339] 95% CI 94.6 to
98.6) [16]. In both instances, the lower effectiveness/efficacy of the granule versus the tablet
was associated with a high rate of vomiting observed in younger children [16]. In the present
study, vomiting occurred in 7.9% (146/1,845) of children under 5 years old versus only 3.1%
(112/3,609) in those aged 5 to 18 years. Similarly, effectiveness tended to be lower in children
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under 1 year old, with 11.2% (15/134) of these infants experiencing vomiting. It is not possible
within this trial to confirm the causality of the lower effectiveness observed for young children
who received the granule formulation. Based on previous data, drug exposure is comparable
between the tablet and granule formulations when all doses are fully supervised [26]. However,
the association with vomiting and difficulties in administering complete doses of oral medica-
tion, even with a specific pediatric granule formulation, are likely to result in lower drug expo-
sures in young children. Also, as young children lack the semi-immunity to malaria that
adolescents and adults acquire in this endemic region, they may also be more sensitive to
underdosing caused by vomiting. Consequently, the finding that antimalarial effectiveness in
children is lower than in adults is not unexpected, though for pyronaridine–artesunate to
achieve high levels of treatment effectiveness under operational conditions, comparable to the
efficacy observed in randomized clinical trials, is encouraging [16].
In the per-protocol population, the difference between PCR-adjusted effectiveness (98.6%
[95% CI 98.3, 98.9]) and unadjusted effectiveness (93.2% [95% CI 92.6, 93.8]) suggests that
around 5% of patients were reinfected within 28 days of pyronaridine–artesunate treatment.
Pyronaridine has a half-life of about 14 to 18 days [19], and posttreatment protection with pyr-
onaridine–artesunate is limited [11]. Also, this population is likely to include patients with
suboptimal adherence. In this case, even if drug exposure was sufficient to clear the initial
infection, the period of posttreatment prophylaxis may have been reduced. Given that malaria
transmission is still substantial in the study areas in general and the observation that individual
patients had multiple malaria episodes during this study, this reinfection rate is not unexpected
and consistent with previous findings [11].
In summary, in this large clinical trial, conducted in a real-world setting in a representative
population of African malaria patients, pyronaridine–artesunate had excellent tolerability,
safety, and effectiveness, and no clinically evident hepatic events occurred in patients with or
without ALT/AST elevations at baseline. The study supports pyronaridine–artesunate as an
operationally valuable therapy for the treatment of acute uncomplicated P. falciparum malaria.
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réné, Lambaréné, Gabon); Rella Zoleko Manego (Centre de Recherches Médicales de Lamba-
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